Wegener's Granulomatosis

Herz

Volumn 29, Issue 1, 2004, Pages 47-56

  Lamprecht, Peter ^b   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

Accelerated arteriosclerosis; Autoimmunity; Effector memory T cell; Endothelial dysfunction; Infection; PR3 ANCA; Th1 type reaction; Wegener's granulomatosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; AUTOIMMUNE DISEASE; COMMON CAROTID ARTERY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; GLOMERULONEPHRITIS; GRANULOMATOUS INFLAMMATION; HEART INFARCTION; HUMAN; MEMORY CELL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; STROKE; SYSTEMIC VASCULITIS; TH1 CELL; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ARTERIAL OCCLUSIVE DISEASES; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELOBLASTIN; PHOSPHOPROTEINS; POLYARTERITIS NODOSA; SERINE ENDOPEPTIDASES; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL MATRIX PROTEINS; WEGENER GRANULOMATOSIS;

EID: 1442279349     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2525-0     Document Type: Review

References (41)

1. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
3. Carrington CB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966;41:497-503.
4. Reinhold-Keller E, deGroot K, Holl-Ulrich K, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 2001;19:541-9.
5. Jayne D, for the European Vasculitis Study Group (EUVAS). Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48-55.
6. Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002;29:309-16.
7. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality and geographic disease distribution from population-based data sources. Arthritis Rheum 1996;39:87-92.
8. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology 2002;41:540-9.
9. Lipsky P. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
10. Gencik M, Borgmann S, Zahn R, et al. Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA) associated systemic vasculitis. Clin Exp Immunol 1999;117:412-7.
11. Peen E, Williams RC Jr. What you should know about PR3-ANCA, structural aspects of antibodies to proteinase 3 (PR3). Arthritis Res 2000;2:255-9.
12. Muraközy G, Gäde KI, Ruprecht B, et al. Gene polymorphism of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. J Mol Med 2001;79:665-70.
13. Edberg JC, Wainstein E, Wu J, et al. Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet 1997;14:183-95.
14. Nikkari S, Vainionpää R, Toivanen P, et al. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1995;38:1175.
15. Meyer MF, Hellmich B, Kotterba S, et al. Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? Rheumatol Int 2000;20:35-8.
16. Popa ER, Stegeman CA, Kallenberg CGM, et al. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002;4:77-9.
17. Voswinkel J, Müller A, Lamprecht P, et al. Does ANCA formation result from an antigen-triggered immune response in Wegener's endonasal inflamed tissue? Cleve Clin J Med 2002;69:Suppl 2:SII-159.
18. Fienberg R. A morphologic and immunohistologic study of the evolution of the necrotizing palisading granuloma of pathergic (Wegener's) granulomatosis. Semin Respir Med 1989;10:126-32.
19. Gross WL. Wegener's granulomatosis. In: Maddison PJ, Isenberg DA, Woo P, et al., eds. Oxford textbook of rheumatology, vol 2, 2nd edn. Oxford: Oxford University Press, 1998:1331-51.
20. Müller A, Trabandt A, Glöckner-Hofmann K, et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-γ expression. J Pathol 2000;192:113-20.
21. + memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Res Ther 2003;5:R25-31.
22. - T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 2003;108:1-7.
23. - T-cells are a major source of IFN-γ and TNF-α in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24.
24. Sneller MC. Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 20002;69:Suppl 2:SII-40.
25. Brons RH, de Jong MC, de Boer NK, et al. Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis. Ann Rheum Dis 2001;60:1097-103.
26. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
27. Hellmich B, Csernok E, Gross WL. 20 years with ANCA (antineutrophil cytoplasmic autoantibodies): from seromarker to a major pathogenic player in vasculitis. J Leukoc Biol 2003;74:1-2.
28. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
29. DeGroot K, Gross WL. Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus 1998;7:285-91.
30. Hagen EC, Daha MR, Hermans J, et al., for the EC/BCR Project for ANCA Assay Standardization. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998;53:743-53.
31. Choi HK, Lamprecht P, Niles JH, et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000;43:226-31.
32. Morelli S, Gurgo di Castelmenardo AM, Conti F, et al. Cardiac involvement in patients with Wegener's granulomatosis. Rheumatol Int 2000;19:209-12.
33. Schmidt WA, Seipelt E, Molsen HP, et al. Vasculitis of the internal carotid artery in Wegener's granulomatosis: comparison of ultrasonography, angiography, and MRI. Scand J Rheumatol 2001;30:48-50.
34. Filer AD, Gardner-Medwin JM, Thambyrajah J, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003;62:162-7.
35. Zänker M, Aries PM, Herlyn K, et al. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a case-control study of arterial wall changes and clinical events. Lancet; submittted.
36. DeGroot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
37. Jayne D, Rasmussen N, Andrassy K, et al., for the European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil autoantibodies. N Engl J Med 2003;349:36-44.
38. Metzler C, Fink C, Lamprecht P, et al. Successful maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004:Epub ahead of print 6. Januar 2004
39. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulamatosis. Rheumatology 2002;41:1303-7.
40. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
41. Birck R, Warnatz K, Lorenz HM, et al. 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.